InvestSMART

AVITA Medical, Inc. (ASX:AVH)

ALERT: Price-sensitive ASX Announcement for AVH
Current share price for AVH : $1.310 0.22 (20.18%)+
Announcement
Release
13 Feb 2026 9:42AM
Price at Release
$1.090
Full Release
download
Summary
AVITA Medical, Inc. reported stable revenue performance for Q4 2025, with significant progress in reimbursement clarity and account utilization normalization at core burn and trauma centers. The company advanced post-market clinical programs for Cohealyx and PermeaDerm and entered 2026 with a strengthened commercial model. Financial results showed a full-year revenue of $71.6 million in 2025, up from $64.3 million in 2024. Operating expenses decreased to $101.4 million in 2025 from $111.8 million in 2024, reducing the net loss to $48.6 million from $61.8 million. AVITA secured a new debt facility with Perceptive Advisors LLC, improving financial terms and supporting 2026 growth expectations with projected revenues of $80 to $85 million.
Key Points
  • Delivered stable revenue performance in Q4 2025.
  • Improved reimbursement clarity and utilization normalization at burn and trauma centers.
  • Advanced post-market clinical programs for Cohealyx and PermeaDerm.
  • Financial results: FY 2025 revenue $71.6M, operating expenses $101.4M, net loss $48.6M.
  • Secured new debt facility with Perceptive Advisors LLC to refinance existing debt.
  • 2026 growth expectations with revenue guidance of $80 to $85 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.